Table 1.
Primers used in this study
| Transcript | Strand | Sequence, 5′–3′ | Product size, bp |
|---|---|---|---|
| Total PGC-1α |
Forward Reverse |
CAGCCTCTTTGCCCAGATCTT TCACTGCACCACTTGAGTCCAC |
101 |
| NT-PGC-1α |
Forward Reverse |
TCACACCAAACCCACAGAGA CTGGAAGATATGGCACAT |
172 |
| TFAM |
Forward Reverse |
AGATTCCAAGAAGCTAAGGGTGATT TTTCAGAGTCAGACAGATTTTTCCA |
85 |
| TFB2 M |
Forward Reverse |
CAAGGAAGGCGTCTAAGGC AGCAGTAGGTGTGGAGGTC |
118 |
| CS |
Forward Reverse |
GAGAAGGCAGCGGTATTG AGGTAAGGGTCGGAAAGG |
196 |
| VEGFA |
Forward Reverse |
TACCTCCACCATGCCAAG GGTACTCCTGGAAGATGTC |
148 |
| TRIM63 (MURF1) |
Forward Reverse |
CTCAGTGTCCATGTCTGGAGGCCGTT GGCCGACTGGAGCACTCCTGTTTGTA |
147 |
| FBXO32 (Atrogin-1) |
Forward Reverse |
GTCCAAAGAGTCGGCAAGTC AGGCAGGTCAGTGAAGGTG |
147 |
| Myostatin |
Forward Reverse |
CATGATCTTGCTGTAACCTTCC CGATAATCCAATCCCATCC |
195 |
| CTSL |
Forward Reverse |
AAGTGGAAGGCTGCAATGGT CTCACACAGTGGGGTAGCTG |
483 |
| BNIP3 |
Forward Reverse |
TCTGGACGGAGTAGCTCCAA TTCATGACGCTCGTGTTCCT |
296 |
| IGF1-Ea |
Forward Reverse |
ATGCTCTTCAGTTCGTGTGTG GCACTCCCTCTACTTGCGTTC |
258 |
| IGF1-Ec (MGF) |
Forward Reverse |
ACCAACAAGAACACGAAGTC CAAGGTGCAAATCACTCCTA |
281 |
| DDIT4 (REDD1) |
Forward Reverse |
GGTTTGACCGCTCCACGAG ATCCAGGTAAGCCGTGTCTTC |
98 |
| RPLP0 |
Forward Reverse |
CACTGAGATCAGGGACATGTTG CTTCACATGGGGCAATGG |
77 |
| GAPDH |
Forward Reverse |
CAAGGTCATCCATGACAACTTTG GTCCACCACCCTGTTGCTGTAG |
496 |